Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Change in Account Payables (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Change in Account Payables for 11 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables changed N/A to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.1 million for FY2025, 486.22% up from the prior year.
  • Change in Account Payables for Q4 2025 was $1.0 million at Crescent Biopharma, up from -$318419.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $1.6 million in Q3 2024, with the low at -$1.0 million in Q2 2022.
  • Average Change in Account Payables over 5 years is $41679.0, with a median of $50861.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables tumbled 390.72% in 2023, then soared 1667.01% in 2024.
  • Over 5 years, Change in Account Payables stood at $717184.0 in 2021, then plummeted by 83.54% to $118066.0 in 2022, then soared by 355.87% to $538230.0 in 2023, then soared by 190.21% to $1.6 million in 2024, then tumbled by 34.44% to $1.0 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $1.0 million, -$318419.0, and -$224633.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.